TY - JOUR
T1 - Coffee consumption and gastric cancer: a pooled analysis from the Stomach cancer Pooling Project consortium
AU - Martimianaki, Georgia
AU - Bertuccio, Paola
AU - Alicandro, Gianfranco
AU - Pelucchi, Claudio
AU - Bravi, Francesca
AU - Carioli, Greta
AU - Bonzi, Rossella
AU - Rabkin, Charles S.
AU - Liao, Linda M.
AU - Sinha, Rashmi
AU - Johnson, Ken
AU - Hu, Jinfu
AU - Palli, Domenico
AU - Ferraroni, Monica
AU - Lunet, Nuno
AU - Lunet, Nuno Miguel De Sousa
AU - Morais, Samantha
AU - Tsugane, Shoichiro
AU - Hidaka, Akihisa
AU - Hamada, Gerson Shigueaki
AU - López-Carrillo, Lizbeth
AU - Hernández-Ramírez, Raúl Ulises
AU - Zaridze, David
AU - Maximovitch, Dmitry
AU - Aragonés, Nuria
AU - Martin, Vicente
AU - Ward, Mary H.
AU - Vioque, Jesus
AU - Garcia De La Hera, Manoli
AU - Zhang, Zuo-Feng
AU - Kurtz, Robert C.
AU - Lagiou, Pagona
AU - Lagiou, Areti
AU - Trichopoulou, Antonia
AU - Karakatsani, Anna
AU - Malekzadeh, Reza
AU - Camargo, M. Constanza
AU - Curado, Maria Paula
AU - Boccia, Stefania
AU - Boffetta, Paolo
AU - Negri, Eva
AU - La Vecchia, Carlo
PY - 2021
Y1 - 2021
N2 - Objective: This study aimed to evaluate and quantify the relationship between coffee and gastric cancer using a uniquely large dataset from an international consortium of observational studies on gastric cancer, including data from 18 studies, for a total of 8198 cases and 21 419 controls.
Methods: A two-stage approach was used to obtain the pooled odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) for coffee drinkers versus never or rare drinkers. A one-stage logistic mixed-effects model with a random intercept for each study was used to estimate the dose-response relationship. Estimates were adjusted for sex, age and the main recognized risk factors for gastric cancer.
Results: Compared to never or rare coffee drinkers, the estimated pooled OR for coffee drinkers was 1.03 (95% CI, 0.94-1.13). When the amount of coffee intake was considered, the pooled ORs were 0.91 (95% CI, 0.81-1.03) for drinkers of 1-2 cups per day, 0.95 (95% CI, 0.82-1.10) for 3-4 cups, and 0.95 (95% CI, 0.79-1.15) for five or more cups. An OR of 1.20 (95% CI, 0.91-1.58) was found for heavy coffee drinkers (seven or more cups of caffeinated coffee per day). A positive association emerged for high coffee intake (five or more cups per day) for gastric cardia cancer only.
Conclusions: These findings better quantify the previously available evidence of the absence of a relevant association between coffee consumption and gastric cancer.
AB - Objective: This study aimed to evaluate and quantify the relationship between coffee and gastric cancer using a uniquely large dataset from an international consortium of observational studies on gastric cancer, including data from 18 studies, for a total of 8198 cases and 21 419 controls.
Methods: A two-stage approach was used to obtain the pooled odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) for coffee drinkers versus never or rare drinkers. A one-stage logistic mixed-effects model with a random intercept for each study was used to estimate the dose-response relationship. Estimates were adjusted for sex, age and the main recognized risk factors for gastric cancer.
Results: Compared to never or rare coffee drinkers, the estimated pooled OR for coffee drinkers was 1.03 (95% CI, 0.94-1.13). When the amount of coffee intake was considered, the pooled ORs were 0.91 (95% CI, 0.81-1.03) for drinkers of 1-2 cups per day, 0.95 (95% CI, 0.82-1.10) for 3-4 cups, and 0.95 (95% CI, 0.79-1.15) for five or more cups. An OR of 1.20 (95% CI, 0.91-1.58) was found for heavy coffee drinkers (seven or more cups of caffeinated coffee per day). A positive association emerged for high coffee intake (five or more cups per day) for gastric cardia cancer only.
Conclusions: These findings better quantify the previously available evidence of the absence of a relevant association between coffee consumption and gastric cancer.
KW - coffee consumption
KW - gastric cancer
KW - coffee consumption
KW - gastric cancer
UR - http://hdl.handle.net/10807/187163
U2 - 10.1097/CEJ.0000000000000680
DO - 10.1097/CEJ.0000000000000680
M3 - Article
SN - 0959-8278
VL - Publish Ahead of Print
SP - 1
EP - 11
JO - European Journal of Cancer Prevention
JF - European Journal of Cancer Prevention
ER -